Supernus Pharmaceuticals, a specialty pharmaceutical company focussed on developing and commercialising products for the treatment of CNS diseases, announced the issuance of a fifth patent (number 8,889,191) by the United States Patent and Trademark Office (USPTO) covering Trokendi XR, its novel once-daily extended-release topiramate product. The patent provides protection for the product with expiration that is no earlier than 2027.

"We are very serious about securing intellectual property protection for our innovative products. This is now the second patent that issued this month on Trokendi XR. We will continue to build our patent estate to provide our products with the protection they are entitled to. We now have patent protection on Oxtellar XR and Trokendi XR through four and five issued US patents, respectively," said Jack A. Khattar, president and chief executive officer of Supernus.

Supernus has several additional patent applications for extended-release topiramate and extended-release oxcarbazepine pending in other geographic regions.

Trokendi XR is the first approved novel once-daily extended release formulation of topiramate for the treatment of epilepsy. Trokendi XR is an antiepileptic drug indicated for initial monotherapy in patients 10 years of age and older with partial onset or primary generalised tonic-clonic seizures; adjunctive therapy in patients 6 years of age and older with partial onset or primary generalised tonic-clonic seizures; and adjunctive therapy in patients 6 years of age and older with seizures associated with Lennox-Gastaut syndrome. The product is available in 25mg, 50mg, 100mg and 200mg extended-release capsules.